SVSushma Verma

Sushma Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sushma Verma has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Emerging Challenges and Mechanisms of Antifungal Drug Resistance: Implications for Treatment and Future Therapeutic Strategies

    by Vishnu Priya, Sushma Verma, Navneet Khurana

    Introduction: Antifungal resistance has become a rapidly growing worldwide issue that severely impairs our ability to effectively treat patients with all forms of systemic (invasive) fungal infections, particularly those who are immunocompromised. For example, growing rates of resistance among Candida auris, azole-resistant Aspergillus fumigatus, and multidrugresistant Candida species are complicating our ability to provide effective therapy to these patients. Methods: We conducted a comprehensive review of major fungal pathogens, resistance mechanisms, clinical patterns/trends in the literature during the past(1) 5 years, and novel therapeutic options for management of antifungal resistance based on evidence from clinical, microbiological, and translational studies involving antifungal resistance, surveillance, and innovative ways to prevent/reduce it. Results: Six major mechanisms of resistance to antifungals have been identified: alterations at the target site, active efflux of the antifungal agent, decreased absorption of the antifungal agent, protection via biofilms, inactivation of antifungal agents via metabolism, and activation of stress-response pathways. Contributing factors to these mechanisms of resistance include inappropriate use of antifungal agents, exposure to azoles through agricultural practices, spread of antifungals in hospitals, biofilms associated with medical devices, and adaptation of fungi through epigenetic modification. The result of these resistance mechanisms is treatment failure, lasting infections, and increased mortality. Discussion: Traditional antifungal agents continue to play an important role in medicine, but they are hampered by either fungi developing resistance over time or their toxicity. This study's findings support the need for more rigorous surveillance, therapeutic drug monitoring, antifungal stewardship, and more stringent regulation on the use of fungicides in agriculture. Potential new approaches to treating fungal infections include immunotherapy directed at the host, new antifungal agents (e.g., ibrexafungerp, olorofim, rezafungin, fosmanogepix), combination therapy with pre-existing and new antifungal agents, utilization of nanotechnology delivery systems, and genomics-guided treatment strategies. Conclusion: Antifungal resistance requires a coordinated, multidimensional response. One Health framework integrating human, animal, agricultural, and environmental sectors is critical to slow resistance and support sustainable antifungal therapy.

  • Open Access

    Synthesis and Biological Evaluation of Pyrazole Derivatives as Anti-Amyloid and Anti-Inflammatory Agents for Alzheimer’s Therapy

    by Mansi Mishra, Sushma Verma, Khushboo Mishra, Anita D. Kadam, Souvik Sur, Gayatri Katole, Rashmi Sharma, Ajay Kumar Yadav, Jannat Ul Firdaus

    Alzheimer's disease (AD) remains a devastating neurodegenerative disorder with no disease-modifying therapies available, largely due to its complex, multifactorial pathophysiology involving amyloid β (Aβ) aggregation, tau hyperphosphorylation, chronic neuroinflammation, oxidative stress, and proteasomal dysfunction. This review comprehensively evaluates the synthesis and biological evaluation of pyrazole derivatives as promising multi-target-directed ligands (MTDLs) for Alzheimer's therapy. The pyrazole scaffold, with its exceptional structural versatility and ease of synthetic modification, has enabled the rational design of diverse compound classes targeting multiple AD-relevant pathways simultaneously. Diphenylpyrazoles function as non-competitive β-secretase (BACE1) modulators, selectively suppressing Aβ production while preserving essential physiological enzyme activity, with the lead compound Anle138b demonstrating remarkable ability to block Aβ pore activity, restore synaptic function, and improve memory in transgenic AD mouse models. Arylpyrazolones (exemplified by compound 1, EC₅₀ = 270 nM) exhibit potent anti-amyloidogenic activity with excellent blood-brain barrier permeation and favorable oral bioavailability. Ferrocene-pyrazole-curcumin analogues show structure-dependent anti-amyloidogenic activity validated by thioflavin T fluorescence and atomic force microscopy, combining natural product inspiration with organometallic fine-tuning. Regarding tau pathology, acylaminopyrazoles inhibit glycogen synthase kinase-3β (GSK-3β) in the low micromolarrange, preventing tau hyperphosphorylation and neurofibrillary tangle formation, while pyrazolones enhance ubiquitin-proteasome system activity, promoting clearance of misfolded proteins and protecting neurons from amyloid-induced toxicity. The collective evidence positions pyrazole-based MTDLs as a chemically feasible, pharmacologically versatile platform for addressing the intricate crosstalk among amyloid pathology, tauopathy, neuroinflammation, and proteostasis failure in Alzheimer's disease, offering genuine hope for next-generation disease-modifying therapeutics.

  • Rheumatoid Arthritis: Current Perspective, Etiology, Signalling Pathway, Diagnosis & Assessment, & ongoing Clinical Trials

    by Priyam Kumar, Sushma Verma, Reenoo Jauhari

    Rheumatoid arthritis (RA) is a chronic autoimmune condition that causes persistent joint inflammation and gradually damages cartilage and bone, leading to pain, deformity, & loss of function. It affects about 0.5-1% of the global population, with women more commonly affected, often between the ages of 40 & 50. The disease develops through an interplay of genetic predisposition & environmental triggers such as smoking, infections, and oral microbiome changes. In many individuals, autoantibodies-including rheumatoid factor and anti-citrullinated protein antibodies-emerge years before the onset of clinical symptoms, marking a preclinical phase of disease. The immune system plays a central role in RA. Overactive macrophages, Tcells, B-cells, & fibroblast-like synoviocytes release proinflammatory mediators and enzymes that damage joint tissues. Several signalling pathways, including JAK/STAT, MAPK, SYK, and BTK, are crucial drivers of this process, making them important therapeutic targets. Diagnosis combines clinical evaluation, serological testing, and imaging studies, guided by the 2010 ACR/EULAR classification criteria. Early and accurate diagnosis is critical to preventing irreversible joint damage. Treatment strategies aim for rapid control of inflammation, sustained remission, and preservation of function. Conventional synthetic DMARDs, particularly methotrexate, remain the cornerstone of therapy, while biologic targeted synthetic DMARDs have improved outcomes for patients with inadequate response to standard treatment. Despite the fact that therapeutic advances have transformed disease management, challenges persist in predicting disease onset, tailoring therapy, & addressing comorbidities. Ongoing research into immune pathways and patient-specific approaches remains vital to advancing prevention and personalized care.

  • Innovative Delivery Systems for the Antifungal Agents

    by Md. Saqlain Mustak, Sushma Verma

    Introduction: Antifungal therapy, DDS, nanotechnology, solid lipid nanoparticles, liposomes, hydrogels, oleogels. Methods: Oleogels were prepared using Aerosil 200 as the gelling agent and a lipid blend of castor oil, paraffin oil, and rapeseed oil. Tween 80 and tocopheryl acetate were incorporated to improve solubilization and stability. A Central Composite Design (CCD) was employed to optimize the concentration of the gelling agent and oil phase. The formulations were evaluated for viscosity, pH, spreadability, homogeneity, drug content, FTIR, DSC, in vitro drug release, and stability. Results: The optimized oleogel exhibited a smooth and homogeneous texture with ideal spreadability and skin-compatible pH. FTIR and DSC confirmed the absence of major drug– excipient interactions, indicating chemical compatibility. The optimized batch demonstrated improved drug release and better diffusion characteristics compared to non-optimized formulations. Stability studies showed no significant change in physicochemical properties over the test period. Discussion: The enhanced release profile and improved diffusion suggest that the oleogel matrix effectively facilitates the partitioning and permeation of itraconazole through the skin layers. The optimized formulation aligns with current trends in lipid-based topical delivery systems and demonstrates a clear advantage over conventional creams and gels. Conclusion: The study successfully developed a stable and efficient itraconazole-loaded oleogel with favourable physicochemical properties and enhanced drug release. These findings support its potential as a promising topical carrier for improved antifungal therapy.

  • Open Access

    Coagulase‐Negative Staphylococci (CoNS): An Emerging Threat, Antimicrobial Resistance, and Health Concern

    by Anushri Keshri, Shivani Choudhary, Anil Kumar, Indu Singh, Haritima Singh, Divakar Sharma, Arun Kumar, Sushma Verma, Arun Ratn

    Coagulase‐negative staphylococci (CoNS) have evolved from a harmless commensal group to an alarming threat to patient, environmental, and population health due to their challenging treatment and their impact on health outcomes. The widespread presence of CoNS in these environments poses a public health concern due to various virulence factors, biofilm formation, and toxin production, which contribute to pathogenicity and antimicrobial resistance (AMR). Major clinical manifestations include device‐related infections, bloodstream infections, and neonatal sepsis. Nonclinical reservoirs, such as soil, water, animals, and food‐processing environments, are considered critical sources of resistance gene flow. The mechanisms of resistance include the mecA gene and a variety of SCCmec elements, as well as horizontal gene transfer via plasmids and transposons, and tolerance via biofilm formation. This review summarizes current findings on the epidemiology, AMR mechanisms, biofilm‐linked pathogenicity, diagnostic advances, and One Health implementations of CoNS across nonclinical and clinical contexts, while recognizing priorities for therapeutic and surveillance development. Here, the reviewed literature suggests considerable variation in drug resistant CoNS and distribution landscapes across nonclinical and clinical contexts, with MGEs, biofilm establishment, and environmental repertoires reflecting imperative determinants in the dissemination and persistence of AMR. An analysis of the existing literature indicates that genetic links between clinical and environmental isolates remain insufficiently established and that surveillance data are lacking; accordingly, future research should focus on these gaps. Addressing the threat of CoNS requires enhanced surveillance, improved diagnostic precision, and the development of novel antimicrobial and antibiofilm strategies. Future research should focus on epidemiological surveillance, innovation in therapy, and systems‐based approaches, which consider the interrelationship of human, animal, and environmental health.

  • Beyond Creams and Gels: The Emergence of Emulgels in Pharmaceutical Science

    by Vikash Singh Bhadouria, Sushma Verma, Rashmi Mishra, Bhupinder Kapoor

    Background: Emulgels combine the properties of emulsions and gels, offering a unique drug delivery system that enhances the solubility and stability of hydrophobic drugs. This study reviews recent advancements in emulgels and their potential in pharmaceutical applications. Objective: To systematically review the current state of research on emulgels, focusing on formulation techniques, characterization methods, and therapeutic applications. Methods: A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science, covering studies published from 2010 to 2023. Inclusion criteria included articles discussing formulation techniques, characterization, and therapeutic applications of emulgels. Data extraction and quality assessment were performed independently by two reviewers. Results: Various formulation techniques, such as high-energy emulsification, phase inversion, and solvent evaporation, have been explored to enhance the bioavailability of hydrophobic drugs. Recent advancements introduced novel methods like microfluidization and ultrasound-assisted emulsification to improve formulation efficiency. Characterization techniques, including rheological analysis, particle size determination, and drug release studies, are crucial for optimizing emulgel formulations. Several patents have been filed, reflecting innovative approaches in emulgel technology, such as incorporating nanomaterials and targeted delivery systems. Therapeutic applications of emulgels have been extensively studied in dermatology, pain management, and antimicrobial therapy, showing promising results in enhancing drug efficacy and patient compliance. Conclusion: Emulgels present a versatile and efficient drug delivery system with significant potential in various therapeutic areas. Future research should focus on the large-scale production of emulgels and their long-term stability to facilitate their transition from research to clinical practice.


  • A Comprehensive Review on Nephrolithiasis: Etiology Recent Advances and Clinical Trials

    by Karan Pal, Sushma Verma, Chhaya Agarwal, Deep Shikha Sharma

    Kidney stone disease, or nephrolithiasis, is a common condition with high morbidity that affects people all over the world. It is important to comprehend the etiology and contemporary developments in its management to enhance patient results. In this study, we describe a thorough analysis of nephrolithiasis, with particular attention to its etiology, current developments in treatment modalities, and ongoing clinical studies by utilizing electronic databases. A thorough search of the literature was carried out to find pertinent papers published through 2024 and the genesis of nephrolithiasis, new treatment developments, and ongoing clinical trials. The review clarifies the complex interplay between dietary variables, metabolic disorders, and genetic susceptibility that leads to nephrolithiasis. The most recent developments in treatment modalities, such as minimally invasive operations and medication therapies, are examined. Furthermore, ongoing clinical trials examining new treatments and preventative measures are emphasized. A multidisciplinary approach is necessary for the optimal care of nephrolithiasis because it is a complex condition influenced by a variety of factors. While ongoing clinical trials hold promise for additional innovation in nephrolithiasis therapy and prevention, recent therapeutic developments offer promising pathways for enhanced patient care. Addressing the difficulties brought on by this common ailment requires cooperation and ongoing study.

  • Open Access

    The Use of Inhaled Nitric Oxide in the Management of Acute Respiratory Distress Syndrome

    by P.R Arthi, Sushma Verma, Simranjeet Nanda, Jatin Khurana, Kasturi Pohini, Banani Jena

    Acute Respiratory Distress Syndrome (ARDS) Patients' Lung Function (PLF), Morbidity (M), and Death were the primary outcomes the researchers were interested in examining. The standard therapy, or the inhaled nitric oxide inhNO treatment, was administered to 30 ARDS patients divided into two groups. It has been shown that 0.5 to 40 ppm of inhNO is the ideal daily dosage. All treatment methods were standard. In 25% of ARDS Patients, sepsis was the underlying cause. In the first 24 hours after inhNO, patients had a considerable increase in their hypoxia score, from 114.2 to 170.4 mm Hg. Similar decreases in venous admixture also occurred in the inhNO group to the control group. InhNO did not continue to have any positive effects beyond the first day of therapy. Forty percent of the inhNO group remained alive and weaned off mechanical ventilation thirty days following randomization, whereas only 33.3% of the control group did so. With Multiple Organ Failure Syndrome (MOFS) as the primary cause of death, the 30-day mortality rate for both groups was comparable. According to the research, inhNO might improve gas exchange but did not lower mortality in this group.

  • Navigating Dry Eye Research: A Comprehensive Review of Etiology, Clinical Trials, Patents, and Recent Advancements

    by Vindhya Pal, Sushma Verma

    Background: Millions of people worldwide suffer from dry eye disease. Dry eye, a multifunctional condition of the ocular surface, typically occurs in conjunction with an unbalanced tear film. With increasing age, the dry eye problem becomes worse. Aqueous-deficit dry eye and evaporative dry eye are the two traditional classifications for dry eye. Various examination tools are used to diagnose dry eye. Clinical trials are conducted in four phases to check the safety and efficacy of drugs. The quick clearance from the precorneal space is ensured by the eye's advanced defense mechanism. It restricts the integrated medicine's entry into the eyes, resulting in a usually low bioavailability for topical eyedrops. In this study, we focus on recently developed formulations for curing dry eye. Objective: This review's goal was to outline the etiology, clinical discovery and development, patents, and recent advancements for dry eye disease. Results: The current study has described the widespread incidence of dry eye, which was found to be more common as people aged and recently developed formulations are treating dry eyes. According to research, novel formulations are enhancing ocular drug delivery. Conclusion: In this review, etiology, clinical data, dry eye formulation patents, and recent advancements are all included.


  • Open Access

    Comprehensive review on herbal remedies treatment for acquired immune deficiency syndrome (AIDS)

    by Sushma Verma, Sushen Singh Choudhary

    This thorough review aimed to present critical examination of the literature on the subject, and assess the effectiveness of herbal medicines for the treatment of acquired immune deficiency syndrome (AIDS). This evaluation presented how herbal medications are used in conventional and...